BioSpace News Archive

Jaguar Health, Inc. announced that the Company’s New Employee Inducement Award Plan, which was adopted by Jaguar’s Board of Directors effective June 16, 2020, has been replenished with 499,171 shares of the Company’s common stock, par value $0.0001 per share.

Celularity Inc. (Nasdaq: CELU) (“Celularity”) announced results from an exploratory analysis of Phase 1 data evaluating alterations in gene and protein signatures associated with reduced inflammation and fistula formation resulting from therapy with mesenchymal‐like adherent stromal cells (MLASCs) in adult patients with Crohn’s disease (CD).

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Dyno Therapeutics, Inc. today announced the launch of its Dyno bCap 1™ capsid product, a breakthrough CNS-targeted AAV gene delivery vector with best-in-class potential, in a keynote address at the company’s Scientific Symposium at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced the Company will present data from RUBY-1, a phase 1 study of povetacicept in healthy adult volunteers, at multiple upcoming scientific congresses, including participation in a poster tour at the European Congress of Rheumatology (EULAR) and an oral presentation at the European Hematology Association (EHA).

DAXOR CORPORATION, the global leader in blood volume measurement technology, announces that it has commenced an underwritten public offering of shares of its common stock.

Helius Medical Technologies, Inc. announced that, effective May 18, 2023, its independent directors approved an equity award under Helius’ 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company.

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced the outcome of the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) Meeting to review the Company’s New Drug Application (NDA) for obeticholic acid (OCA) for the treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH).